We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 26 MAY 2004
To Negate Public Use Bar Experimental Use Must Be Limited to Perfecting Claimed Features
McDermott Will & Emery
Reversing the district court’s erroneous claim construction, the U.S. Court of Appeals for the Federal Circuit held that Apotex’s product infringed SmithKline Beecham’s (now GlaxoSmithKline’s) claim covering the active ingredient of the antidepressant Paxil, but further held the claim invalid because SmithKline’s clinical tests prior to one year before filing constituted a public use not qualifying under the experimental use exception.
United StatesIntellectual Property







